DUBLIN--(BUSINESS WIRE)--The "Global Oncology Drug Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering.
The global oncology drug market was estimated at US$199.933 billion for the year 2019.
The growing prevalence of cancer is the prime factor that is significantly driving the global oncology drugs market growth throughout the forecast period. Cancer is a type of disease in which abnormal cells grow and forms a tumor, these cells have the potential spread throughout the body through the blood and lymphatic system and may damage the body part and in the worst case may lead to death. The demand for cancer drugs is growing significantly throughout the globe due to the rising prevalence of different types of cancer around the world. In addition, the continuous investments in the form of R&D for the development of new drugs is also projected to bolster the oncology drugs market during the forecast period and beyond. The increasing healthcare expenditure is also one of the factors which is expected to augment the growth opportunities for the drug manufacturers in the coming years.
According to the World Health Organization, cancer is the second leading cause of death globally, with an estimated 9.6 million deaths worldwide in 2018, and this number is on the rise. Furthermore, the rise in the geriatric population is also resulting in the increasing number of cancer cases because the process of aging favors two essential processes in cancer development: the acquisition of mutations and the formation of a molecular and cellular environment that favors carcinogenesis. According to the American Cancer Society, Inc. nearly nine out of ten cancers are diagnosed in people over the age of 50. Increasing consumption of tobacco and alcohol is also the reason for the increasing number of cancer cases but the consumption of both of them together further worsens their effect. In addition, rising pollution and environmental changes have also led to the rising concentration of carcinogens in the air which is further responsible for increasing the prevalence of cancer.
In addition, it is estimated that the estimated number of incident cases for all types of cancer will increase from 18,078,957 in 2018 to 29,532,99 by 2040 (Source: GLOBOCAN 2018, World Health Organization). Therefore, the growing number of cancer cases is anticipated to significantly drive the demand for oncology drugs during the next five years. Similarly, according to the data provided by the U.S. Department of Health and Human Services, the new number of cancer cases is expected to increase to 1.9 million people per year by 2020 from 1.5 million people per year in 2010.
Prominent key market players in the global oncology drug market include F. Hoffmann-La Roche Ltd, Novartis AG, Bayer AG, Merck & Co., Inc., and Johnson & Johnson Services, Inc. among others. These companies hold a noteworthy share in the market on account of their good brand image and product offerings.
Major players in the global oncology drug market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last two years.
Key Topics Covered:
1.1. Market Definition
1.2. Market Segmentation
2. Research Methodology
2.1. Research Data
3. Executive Summary
3.1. Research Highlights
4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. Global Oncology Drug Market Analysis, By Type of Cancer
5.2. Lung Cancer
5.3. Blood Cancer
5.4. Breast Cancer
5.5. Liver Cancer
6. Global Oncology Drug Market Analysis, By Geography
6.2. North America
6.3. South America
6.5. Middle East and Africa
6.6. Asia Pacific
7. Competitive Environment and Analysis
7.1. Major Players and Strategy Analysis
7.2. Emerging Players and Market Lucrativeness
7.3. Mergers, Acquisitions, Agreements, and Collaborations
7.4. Vendor Competitiveness Matrix
8. Company Profiles
8.1. AbbVie Inc.
8.2. F. Hoffmann-La Roche Ltd
8.3. Novartis AG
8.5. Johnson & Johnson Services, Inc.
8.6. Bayer AG
8.7. Merck & Co., Inc.
8.8. Bristol-Myers Squibb Company
8.9. Astellas Pharma Inc.
For more information about this report visit https://www.researchandmarkets.com/r/f62qgw